Genelux Corp
GNLX
Company Profile
Business description
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
Contact
2625 Townsgate Road
Suite 230
Westlake VillageCA91361
USAT: +1 805 267-9889
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
24
Stocks News & Analysis
stocks
Undervalued by 17%, this US cybersecurity leader is a buy for 2026
Here’s a wide-moat company with strong secular tailwinds in a promising industry—and an attractive stock price, too.
stocks
Tough conditions for ASX listed wagering leader
Wagering continues to be challenged in Australia.
stocks
Chart of the Week: Inflation fears dampen sentiment on retailers
Rising inflation is the fly in the ointment.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,059.20 | 14.50 | -0.16% |
| CAC 40 | 8,243.47 | 9.55 | 0.12% |
| DAX 40 | 25,127.46 | 5.20 | 0.02% |
| Dow JONES (US) | 49,266.11 | 270.03 | 0.55% |
| FTSE 100 | 10,044.69 | 3.52 | -0.04% |
| HKSE | 26,149.31 | 309.64 | -1.17% |
| NASDAQ | 23,480.02 | 104.26 | -0.44% |
| Nikkei 225 | 51,117.26 | 844.72 | -1.63% |
| NZX 50 Index | 13,719.31 | 2.45 | 0.02% |
| S&P 500 | 6,921.46 | 0.53 | 0.01% |
| S&P/ASX 200 | 8,729.80 | 17.10 | -0.20% |
| SSE Composite Index | 4,082.98 | 2.79 | -0.07% |